echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Johnson and Johnson Darzalex combination of first-line treatment AL Phase III Clinical: Hematology remission rate as high as 92%

    Johnson and Johnson Darzalex combination of first-line treatment AL Phase III Clinical: Hematology remission rate as high as 92%

    • Last Update: 2020-06-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Original source: Subcutane Daratumab Combination Results in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in The Treatment of Patients with Diagnosed Light Chain (AL) Amyloidosisthe original title: Light Chain (AL) amyloid degeneration first therapy! Johnson and Johnson subcutaneous Darzalex combination first-line therapy Phase III Clinical: Hematology remission rate as high as 92%
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.